Introduction: Although histological subtype in lung adenocarcinoma has been reported as a poor prognostic factor in several studies, its utility has not yet been revealed as an adaptation criterion of postoperative adjuvant chemotherapy. Methods: Four hundred ninety-four lung adenocarcinoma patients were enrolled in this retrospective study. A subanalysis was performed in 420 lung adenocarcinoma patients with pathological stage 0–I disease for risk factors of postoperative recurrence. Results: Maximum standardized uptake value (SUVmax) (p < 0.01), pathological stage ≥II (p < 0.04), and adjuvant chemotherapy (p < 0.01) were risk factors for recurrence in the multivariate analysis, whereas histological subtype was not a significant factor for recurrence at all stages. In the subanalysis, univariate analysis showed that carcinoembryonic antigen expression (p < 0.01), prognostic nutrition index (p = 0.03), SUVmax (p < 0.01), lymphatic invasion (p < 0.01), vascular invasion (p < 0.01), grade 3–4 differentiation (p < 0.01), pathological stage ≥IA3 (p < 0.01), and histological subtype (p = 0.03) were significant risk factors of recurrence. SUVmax (p < 0.01) was the only risk factor for recurrence in the multivariate analysis, whereas histological subtype was not (p = 0.07). Relapse-free survival (RFS) was significantly worse in the micropapillary- and solid-predominant subtype groups than in the other subtypes (p = 0.01). On the other hand, RFS with or without uracil-tegafur as adjuvant chemotherapy in lung micropapillary- or solid-predominant adenocarcinoma patients with pathological stage IA-IB disease was not significantly different. Conclusion: This study suggested that histological subtypes, such as micropapillary- or solid-predominant pattern, are risk factors for recurrence in pathological stage 0-I lung adenocarcinoma and may be necessary adjuvant chemotherapy instead of uracil-tegafur.

1.
Siegel
RL
,
Miller
KD
,
Jemal
A
.
Cancer statistics, 2018
.
CA Cancer J Clin
.
2018
;
68
(
1
):
7
30
.
2.
Travis
W
,
Brambilla
E
,
Noguchi
M
,
Nicholson
A
,
Geisinger
K
,
Yatabe
Y
et al
.
International association for the study of lung cancer/American Thoracic Society/European Respiratory Society international multidisciplinary classification of lung adenocarcinoma
.
J Thorac Oncol
.
2011
;
6
(
2
):
244
85
.
3.
Mansuet-Lupo
A
,
Bobbio
A
,
Blons
H
,
Becht
E
,
Ouakrim
H
,
Didelot
A
et al
.
The new histologic classification of lung primary adenocarcinoma subtypes is a reliable prognostic marker and identifies tumors with different mutation status: the experience of a French cohort
.
Chest
.
2014
;
146
(
3
):
633
43
.
4.
Zugazagoitia
J
,
Enguita
AB
,
Nuñez
JA
,
Iglesias
L
,
Ponce
S
.
The new IASLC/ATS/ERS lung adenocarcinoma classification from a clinical perspective: current concepts and future prospects
.
J Thorac Dis
.
2014
6
Suppl 5
S526
536
.
5.
Russell
PA
,
Wainer
Z
,
Wright
GM
,
Daniels
M
,
Conron
M
,
Williams
RA
.
Dose lung adenocarcinoma subtype predict patient survival? A clinicopathologic study based on the new International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society international multidisciplinary lung adenocarcinoma classification
.
J Thorac Oncol
.
2011
;
6
(
9
):
1496
504
.
6.
Motono
N
,
Matsui
T
,
Machida
Y
,
Usuda
K
,
Uramoto
H
.
Prognostic significance of histologic subtype in pStage I lung adenocarcinoma
.
Med Oncol
.
2017
;
34
(
6
):
100
.
7.
Zhang
Y
,
li
J
,
Wang
R
,
Li
Y
,
Pan
Y
,
Cai
D
et al
.
The prognostic and predictive value of solid subtype in invasive lung adenocarcinoma
.
Sci Rep
.
2014
;
4
:
7163
.
8.
Zhao
Y
,
Wang
R
,
Shen
X
,
Pan
Y
,
Cheng
C
,
Li
Y
et al
.
Minor components of micropapillary and solid subtypes in lung adenocarcinoma are predictors of lymph node metastasis and poor prognosis
.
Ann Surg Oncol
.
2016
;
23
(
6
):
2099
105
.
9.
Zhang
H
,
Huang
W
,
Liu
C
,
Giaccone
G
,
Zhao
X
,
Sun
X
et al
.
The prognostic value of non-predominant micropapillary pattern in a large cohort of resected invasive lung adenocarcinoma measuring ≤3 cm
.
Front Oncol
.
2021
;
11
:
657506
.
10.
Jhala
H
,
Harling
L
,
Rodrigo
A
,
Nonaka
D
,
Mclean
E
,
Ng
W
et al
.
Clinicopathological predictors of survival in resected primary lung adenocarcinoma
.
J Clin Pathol
.
2022
;
75
(
5
):
310
5
.
11.
Nitadori
J
,
Bograd
AJ
,
Morales
EA
,
Rizk
NP
,
Dunphy
MPS
,
Sima
CS
et al
.
Preoperative consolidation-to-tumor ratio and SUVmax stratify the risk of recurrence in patients undergoing limited resection for lung adenocarcinoma ≤2 cm
.
Ann Surg Oncol
.
2013
;
20
(
13
):
4282
8
.
12.
Brinkman
GL
,
Coates
EO
.
The effect of bronchitis, smoking, and occupation on ventilation
.
Am Rev Respir Dis
.
1963
;
87
:
684
93
.
13.
Li
D
,
Yuan
X
,
Liu
J
,
Li
C
,
Li
W
.
Prognostic value of prognostic nutritional index in lung cancer: a meta-analysis
.
J Thorac Dis
.
2018
;
10
(
9
):
5298
307
.
14.
Qiu
C
,
Qu
X
,
Shen
H
,
Zheng
C
,
Zhu
L
,
Meng
L
et al
.
Evaluation of prognostic nutritional index in patients undergoing radical surgery with nonsmall cell lung cancer
.
Nutr Cancer
.
2015
;
67
(
5
):
741
7
.
15.
Zahorec
R
.
Ratio of neutrophil to lymphocyte counts: rapid and simple parameter of systemic inflammation and stress in critically ill
.
Bratisl Lek Listy
.
2001
;
102
(
1
):
5
14
.
16.
Shimizu
K
,
Okita
R
,
Saisho
S
,
Maeda
A
,
Nojima
Y
,
Nakata
M
.
Preoperative neutrophil/lymphocyte ratio and prognostic nutritional index predict survival in patients with non-small cell lung cancer
.
J Surg Oncol
.
2015
;
13
:
291
.
17.
Mizuguchi
S
,
Izumi
N
,
Tsukioka
T
,
Komatsu
H
,
Nishiyama
N
.
Neutrophil-lymphocyte ratio predicts recurrence in patients with resected stage 1 non-small cell lung cancer
.
J Cardiothorac Surg
.
2018
;
13
:
78
.
18.
Kim
YS
,
Kim
SJ
,
Kim
YK
,
Kim
IJ
,
Kim
YD
,
Lee
MK
.
Prediction of survival and cancer recurrence using F-18 FDG PET/CT in patients with surgically resected early stage (stage I and II) non-small cell lung cancer
.
Neoplasma
.
2011
;
58
(
3
):
245
50
.
19.
Motono
N
,
Ueno
M
,
Tanaka
M
,
Machida
Y
,
Usuda
K
,
Sakuma
T
et al
.
Differences in the prognostic significance of the SUVmax between patients with resected pulmonary adenocarcinoma and squamous cell carcinoma
.
Asian Pac J Cancer Prev
.
2014
;
15
(
23
):
10171
4
.
20.
Felip
E
,
Altorki
N
,
Zhou
C
,
Csőszi
T
,
Vynnychenko
I
,
Goloborodko
O
et al
.
Adjuvant atezolizumab after adjuvant chemotherapy in resected stage IB–IIIA non-small-cell lung cancer (IMpower010): a randomised, multicentre, open-label, phase 3 trial
.
Lancet
.
2021
;
398
(
10308
):
1344
57
.
21.
Wu
YL
,
John
T
,
Grohe
C
,
Majem
M
,
Goldman
JW
,
Kim
SW
et al
.
Postoperative chemotherapy use and outcomes from ADAURA: osimertinib as adjuvant therapy for resected EGFR-mutated NSCLC
.
J Thorac Oncol
.
2022
;
17
(
3
):
423
33
.
22.
Kato
H
,
Ichinose
Y
,
Ohta
M
,
Hata
E
,
Tsubota
N
,
Tada
H
et al
.
A randomized trial of adjuvant chemotherapy with uracil-tegafur for adenocarcinoma of the lung
.
N Engl J Med
.
2004
;
350
(
17
):
1713
21
.
23.
Tsutani
Y
,
Imai
K
,
Ito
H
,
Miyata
Y
,
Ikeda
N
,
Nakayama
H
et al
.
Adjuvant chemotherapy for high-risk pathologic stage I non-small cell lung cancer
.
Ann Thorac Surg
.
2022
;
113
(
5
):
1608
16
.
You do not currently have access to this content.